Key Takeaway: Acrivon has advanced its investigational drug ACR-2316, a potential first-in-class WEE1/PKMYT1 inhibitor, into the randomized dose expansion phase of its ongoing Phase 1/2 study. The drug has demonstrated a favorable safety profile and durable clinical activity, particularly in heavily pretreated lung cancer patients. The selected oral regimen includes a weekly dosing schedule.
Market Sentiment Analysis
POSITIVE FACTORS
Favorable safety profile for ACR-2316.
Durable clinical activity in heavily pretreated lung cancer patients.
Long treatment duration of over a year for some subjects.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+29%
120-day peak, hindsight
Typical move
9.9%
average across 2 past catalysts
Cash runway
~12 mo
Medium dilution risk
Lead asset
ACR-2316
Phase 1 · Specific Advanced Solid Tumors
Full Press Release Details
Favorable, differentiated safety profile and durable single-agent clinical activity, including in heavily pretreated subjects with lung cancer remaining on treatment for over a year Oral weekly regimen (3 days on/4 days off) at 120 mg and 160 mg QD dose levels selected for randomized dose
Frequently Asked Questions
What is ACR-2316?
ACR-2316 is a potential first-in-class WEE1/PKMYT1 inhibitor developed by Acrivon.
What phase is ACR-2316 currently in?
ACR-2316 is currently in the randomized dose expansion phase of a Phase 1/2 study.
What is the dosing regimen for ACR-2316?
The dosing regimen for ACR-2316 is an oral weekly schedule of 120 mg and 160 mg.
How effective is ACR-2316 in lung cancer patients?
ACR-2316 has shown durable clinical activity in heavily pretreated lung cancer patients.